Zydus Lifesciences Limited has received final approval for Levothyroxine Sodium for injection, 100 mcg/vial, 200 mcg/vial, and 500 mcg/vial from the United States Food and Drug Administration (USFDA), as per an exchange filing.
Levothyroxine Sodium Injection is indicated for the treatment of myxedema coma.
The drug will be manufactured at the group’s injectable manufacturing facility at Jarod, near Vadodara (India).
The group now has 354 approvals and has so far filed over 440 ANDAs since the commencement of the filing process in FY 2003-04.
Mumbai Sessions Court Grants Anticipatory Bail To Thane Resident In ₹10 Crore Gold Investment Fraud Linked To Dabba Trading
Mumbai special PMLA Court Rejects Bail Plea Of Ex-Axis Mutual Fund Manager Viresh Joshi In ₹91 Crore Front Trading Case
Vasai-Virar Illegal Construction Scam: ED Gets Custody Of Suspended Ex-VVCMC Deputy Director YS Reddy In Money Laundering Case
Mumbai News: 3 RPF Personnel Accused Of Extorting Passenger At Mumbai Central Move Bombay HC For Anticipatory Bail
